| HOME >> MEDICINE >> TECHNOLOGY |
Dr Lisa Murphy, Senior Scientist, NIBRT Laboratory, National Institute for Cellular Biotechnology (NICB), Dublin City University, Ireland
1. Introduction
2. Interventions in the protein secretory pathway
3. Disulphide bond formation
4. Chaperones
5. Multiple gene activators
6. Environmental conditions
7. Analytical methods to detect misfolding and aggregation
8. Conclusions
Chapter 11
Importance of Non-Clinical Testing
Nadja Prang-Richard PhD MBA, Program Director for Monoclonal Antibodies, LFB, France and Co-Founder & Scientific Advisory Board Member, Lophius, Biosciences, Germany
1. Introduction
2. Regulatory aspects
3. In vitro systems
4. In vivo systems
5. Pharmacokinetics
6. Toxicology studies
7. Non-clinical testing in (BIO)pharmaceutical development
Part Four: Regulatory Considerations Regarding Product Quality
Chapter 12
Current Safety and Efficacy Concerns of the Regulatory Authorities
Frits Lekkerkerker MD, Former CHMP Member and Chairman, Medicines Evaluation Board, Netherlands, Member Advisory Board, NDA Regulatory Science Ltd
1. History
2. New regulatory guidance
3. Expectations of the regulatory authorities
4. Where the industry tends to go wrong
5. Will biologicals become harder to regulate?
Chapter 13
Requirements for an Effective CMC Regulatory Compliance Strategy
Steffen Gross, PhD, Laboratory Head and Scientific Assessor (Quality, Pre-clinic Section Monoclonal and Polyclonal Antibodies, Paul-Ehrlich-Institute, Germany
1. Introduction
2. CMC requirements for dossier filing
3. Development of a product - interaction with regulatory authorities
Chapter 14
Regulatory Considerations in Performing Comparability Studies for Biotechnology Products: An Industry Perspective
Wassi
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |